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Abstract
Background—Surgery for severe mitral regurgitation (MR) is indicated if symptoms or LV 
dilation/ dysfunction occur. However, prognosis is already reduced by this stage and earlier 
surgery on asymptomatic patients has been advocated if valve repair is likely, but identifying 
suitable patients for early surgery is difficult. Quantifying the regurgitation may help, but 
evidence for its link with outcome is limited. Cardiovascular magnetic resonance (CMR) can 
accurately quantify MR, and we examined whether this was associated with the future need for 
surgery.
Methods and Results—109 asymptomatic patients with echocardiographic moderate or severe 
MR had baseline CMR scans and were followed for up to 8 years (mean 2.5±1.9 years). CMR 
quantification accurately identified patients who progressed to symptoms or other indications for 
surgery: 91% of subjects with regurgitant volume ?55ml survived to 5 years without surgery 
compared to only 21% with regurgitant volume >55ml (p<0.0001); similar separation was 
observed for regurgitant fraction below and above 40%. CMR-derived end-diastolic volume 
index showed a weaker association with outcome (proportions surviving without surgery at 5 
years: 90% for LVEDVi <100ml/m2 versus 48% for ?100ml/m2) and added little to the 
discriminatory power of regurgitant fraction/volume alone.
Conclusions—CMR quantification of mitral regurgitation was associated with the development 
of symptoms or other indications for surgery, and showed better discriminatory ability than 
‘reference-standard’ CMR-derived ventricular volumes. CMR may be able to identify 
appropriate patients for early surgery, with the potential to change clinical practice, though the 
clinical benefits of early surgery require confirmation in a clinical trial.
Key words: mitral regurgitation; prognosis; outcome; cardiovascular magnetic resonance 
imaging; mitral valve 
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Background 
Mitral regurgitation (MR) is usually well tolerated, and even those with severe asymptomatic 
regurgitation can survive many years, though around a third develop indications for surgery by 5 
years.1  Mitral valve repair or replacement is indicated once symptoms or adverse cardiac 
features develop2 (e.g. left ventricular dysfunction/excess dilation), as prognosis is significantly 
reduced without treatment.3-5 However, even with surgery prognosis may be reduced at this stage, 
and early surgery for severe regurgitation has been advocated.6, 7 The latest guidelines now 
consider this to be ‘reasonable’ (class 2a indication) if severe MR is present, the chance of mitral 
repair is high (>95%), and the surgery is carried out in a centre of excellence with a very low 
mortality, or other conditions exist (pulmonary hypertension or new onset atrial fibrillation).2 
This ‘aggressive’ approach has to be balanced against the favourable natural history of untreated 
mitral regurgitation without symptoms or other adverse features, and the risks of early surgery, 
particularly in an elderly population in whom the risks of surgery are higher. There is therefore 
considerable debate between those who advocate a ‘watchful waiting’ strategy1 versus those who 
favour early surgery.8, 9 Determining the correct clinical approach is hindered by the lack of any 
controlled trial of early surgery, and the difficulty in identifying which patients should be offered 
this while asymptomatic. Advance identification of those patients likely to progress to symptoms 
or other indications for surgery in the near future could highlight the group most likely to benefit, 
and facilitate early surgery before prognosis was reduced.  
Quantifying the MR in those with significant regurgitation (rather than qualitative 
grading) might be one method to identify such patients. This can be achieved with 
echocardiography (Echo),10 though Echo quantitation is primarily used to aid grading into mild, 
moderate and severe regurgitation,10 rather than identifying patients for surgery. One important 
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study has shown an association of quantitative Echo MR grading with mortality in medically-
treated patients,11 but this did not address the identification of patients for surgery.  
Cardiovascular magnetic resonance (CMR) is able to quantify mitral regurgitation with 
high accuracy and reproducibility, using a combination of left ventricular (LV) volumetric 
measurement and aortic flow quantification with phase contrast velocity mapping.12 Given that 
left ventricular (LV) volumes and function are also important for MR assessment, and that CMR 
is considered the ‘reference-standard’ method for measuring these,13 it would appear to be an 
optimal technique for the assessment of mitral regurgitation. We previously used this technique 
in patients with aortic regurgitation, and demonstrated a strong association of the quantification 
of regurgitation with outcome.14 We therefore sought to examine whether a similar approach 
using CMR quantitation of mitral regurgitation and LV indices might be able to predict which 
asymptomatic patients with significant (moderate or severe) MR were likely to progress to 
symptoms or other established indications for surgery. We also aimed to compare the CMR 
quantitation of mitral regurgitation and LV volume/function indices for their relative predictive 
ability. 
 
Methods
Subjects and follow up 
Patients at least 18 years of age were recruited from four high-volume CMR centres in Oxford, 
Leeds, London (UK) and Auckland (New Zealand). All asymptomatic patients with moderate or 
severe chronic organic mitral regurgitation on echocardiography were eligible for inclusion and 
underwent baseline CMR scanning. Exclusion criteria included the presence of ‘functional’ 
mitral regurgitation (secondary to annular dilation or LV dysfunction), other significant valve 
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disease and clinical and/or angiographic evidence of coronary disease.  
Subjects were followed for up to 8 years. Those who remained asymptomatic and under 
conservative management were designated the ‘conservative’ group, while those who developed 
symptoms or other established indications for surgery2 were designated the ‘crossover’ group, 
with the decision for surgery taken as the point of censoring. Subjects were only included in the 
crossover group if the surgery was indicated on established criteria,2 which do not include CMR 
assessment. Any subjects undergoing mitral valve replacement/repair for indications outside 
these criteria (including mitral repair performed for asymptomatic severe MR without other 
indications of adverse prognosis) remained in the conservative group but were censored at the 
time of surgery. In addition, a minimum period of one month was required between the CMR 
scan and the decision for surgery, to avoid the potential bias of patients having a predesignated 
CMR scan ‘en-route’ to surgery. All clinical decisions were taken by the treating physician. In 
Oxford, patients participated in a research study, and clinical decisions were made without 
knowledge of the CMR data. In the other three centres, study patients were identified from the 
clinical CMR databases (having been initially diagnosed with Echo) and clinicians had access to 
the CMR data, although as indicated above, there are no CMR-based criteria for surgery. 
A third group was also included to compare CMR parameters with both the conservative 
and crossover groups. This group included patients who had already developed established 
indications for surgery2 and were scheduled for mitral valve repair/replacement (the ‘surgical’ 
group). They underwent identical CMR scans to the other groups. 
The research study was approved by the Oxfordshire Central Research Ethics Committee 
(Project code C02.020) and the Waitemata District Health Board “Knowledge Centre” in New 
Zealand (Project number RM0980711302); all research subjects gave written informed consent. 
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CMR scanning 
All scans were performed on clinical 1.5 Tesla scanners (Siemens Avanto [Siemens Medical 
Solutions, Erlangen, Germany] or Philips Intera [Philips Healthcare, Best, Netherlands] and 
analysed in each centre using dedicated software (Argus [Siemens], CMR42 [Circle 
Cardiovascular Imaging, Calgary, Canada] or CMRtools [Cardiovascular Imaging Solutions, 
London, UK]) for both volumes and flow, according to standard acquisition guidelines.12 All 
images were electrocardiogram (ECG)-gated and most were obtained during an 8-16 second 
breath-hold to remove cardiac motion due to the respiratory cycle.  Subjects underwent a left 
ventricular function study, consisting of a stack of contiguous short axis cine images from base 
to apex, from which left ventricular end-diastolic and end-systolic volumes (LVEDV and 
LVESV respectively) and mass were measured, and LV stroke volume (LVSV) was derived 
from: LVEDV-LVESV. Each value was also indexed to body surface area. Cine image 
sequences were steady-state free precession; temporal resolution 35-45msec; echo time 1.40-
1.54msec; repetition time 2.80-3.08msec; field of view 380x380mm; flip angle 50-60o). 
Aortic forward flow was quantified using through-plane phase-contrast velocity-mapping 
as previously described,15, 16 with the image plane placed either just above the aortic valve at 
end-diastole or at the sinotubular junction (Figure 1). If significant turbulence or aliasing was 
seen in the velocity image, the acquisition was repeated a few millimetres further from the valve, 
and/or with a higher velocity window. Free-breathing flow sequences were used in Oxford, while 
breath-hold flow sequences were used in the other three centres. Our previous work has shown 
that the choice of pulse sequence (free-breathing versus breath-hold) does not significantly affect 
the quantitative results.14 In all centres, the potential for background flow offset errors was 
reduced17 by ensuring flow sequences were acquired with the region of interest located at the 
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isocentre of the magnet to minimise any inhomogeneities in the magnetic field. Image 
parameters: temporal resolution 25-55msec; echo time 2.6-3.2msec; repetition time 4.3-7.8msec; 
field of view 320x320mm; velocity window 2.0-2.5m/sec; signal averages: 1 for breath-hold 
sequences, 3 for free-breathing sequences; typical acquisition time 12-16 seconds for breath-hold 
sequences, 2-3 minutes for free-breathing sequences. 
Standard CMR quantification of MR involves the deduction of aortic flow from LV 
stroke volume (LVSV – aortic forward flow). In the absence of inter-ventricular shunting, this 
equates to the volume of mitral regurgitation. This technique is robust in the presence of 
changing degrees of MR during systole, in addition to eccentric and/or mobile mitral regurgitant 
jets. Regurgitant fraction was also determined (regurgitant volume/LV stroke volume x 100%). 
Echocardiography
Transthoracic echocardiograms were acquired for clinical management a mean of 47.1 ±71.6 
days from the baseline CMR scan, according to standard protocols.18 The images for the 
prospectively followed subjects (conservative and crossover groups) were re-assessed by the 
researchers, blinded to CMR and outcome data, and determination of the grade of MR on 
echocardiography was made. This was based on multiple two-dimensional imaging parameters, 
as described in the American Society of Echocardiography guidelines.10 These were both 
qualitative and semi-quantitative, and quantitative assessments were used wherever feasible 
(including assessment of effective regurgitant orifice area (EROA) by the proximal 
isovolumetric surface area method19) if accurate measurements could be obtained.  
Data assessment and statistical analysis 
Receiver operating characteristic (ROC) analysis was used as the initial test to identify the 
imaging parameters with a reasonable ability (area under the curve [AUC] >0.75) to identify 
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patients who would develop symptoms or other indications for surgery during follow up. The 
optimal threshold for sensitivity and specificity was determined using the Youden index. Step-
wise Cox proportional-hazards regression analysis was also performed on these parameters to 
determine which were independent predictors. 
Kaplan-Meier survival curves are more appropriate for assessing the occurrence of events 
over time, and these were generated for parameters with an ROC AUC >0.70 to identify the 
strongest predictors. There are however no existing CMR thresholds for regurgitation severity to 
determine the sub-groups for comparing progression over time. In addition, it is likely that there 
is an increasing (continuous) risk with increasing regurgitation/ventricular size, and a single 
threshold may not necessarily be appropriate. To determine the best cut-off thresholds for 
separating groups, Cox proportional hazards was used, with each parameter investigated 
separately in a univariate Cox model. The factors were dichotomised at different cut-off levels, 
and discrimination was assessed by Harrell’s C and Somers’ D statistics. The cut-off thresholds 
with the highest Harrell’s C and Somers’ D statistics were used to separate groups in the survival 
analyses. 
All analyses were performed with SPSS version 20.0 (SPSS Inc., Chicago, USA) with the 
exception of the ROC analyses which were performed with MedCalc version 9.3.1 (MedCalc 
Software, Mariakerke, Belgium), and the Cox proportional hazards assessment of different cut-
off thresholds, which was performed in ‘R’ version 3.2.3. Values shown are means ?standard 
deviation and a p-value of <0.05 was considered the threshold for statistical significance. 
Results
109 asymptomatic patients with at least moderate MR on echocardiography were included in the 
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study and followed for up to 8 years (mean 2.5 ± SD 1.9 years; median 1.6 years; 25th percentile 
0.8 years; 75th percentile 3.5 years). Twenty five patients (23%) underwent mitral valve 
repair/replacement during the follow-up period (the ‘crossover’ group), having developed 
symptoms (n=19) or other established echocardiographic indications for surgery (excessive LV 
dilation [ESD >4.0cm], n=4; or pulmonary hypertension [>50mmHg] with a repairable valve, 
n=2). The mean time from CMR scan to the decision on surgery in this group was 1.9 years 
(median: 1.1 years; 25th and 75th percentiles 0.4 and 3.0 years respectively), with 85% of events 
occurring within four years. Seven patients underwent mitral surgery but did not have 
conventional indications, and remained in the ‘conservative’ group, though censored at the time 
of surgery. The surgery in these seven subjects was mainly mitral repair for severe MR but 
without clear indications of adverse prognosis; the mean regurgitant fraction was 36% (range 26-
56%).  
Association with the need for surgery 
The ROC analyses identified several baseline CMR parameters associated with the development 
of indications for surgery (table 1). Quantitative measures of MR (mitral regurgitant volume and 
fraction) both had a high area under the curve (AUC), with good sensitivity and specificity. 
CMR LV volumetric indices also showed good discriminatory ability. LV mass showed some 
predictive power, but this parameter is closely related to LVEDV, and the similar mass:volume 
ratios in all groups (table 2) suggests that LVEDV is likely to be the main determinant of LV 
mass. Cox regression analysis showed independent associations for regurgitant volume (b 
exponent 1.03 [95% CI 1.01-1.05] per ml increase, p=0.01), and for regurgitant fraction (b 
exponent 1.05 [95% CI 1.01-1.09] per % increase, p=0.01) if assessed separately from 
regurgitant volume – this was otherwise too closely related. Assessment of the best dichotomous 
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cut-off threshold for discrimination of the need for surgery was performed for regurgitant 
volume, regurgitant fraction and LVEDVindex. For regurgitant volume, cut-off levels between 
30 and 65 ml were analysed using Cox proportional hazards, and the highest values of the 
Harrell’s C and Somers’ D statistics were associated with a cut-off threshold of 55 ml. For 
regurgitant fraction, cut-off levels between 20 and 50% were investigated, and the optimum cut 
off level was 40%. For LVEDVindex, cut-off levels between 80 and 130 ml/m2 were 
investigated, and the optimum cut off level was 100 ml/m2. These thresholds were then used to 
separate sub-groups in the survival analyses. 
CMR measures of regurgitation demonstrated substantial separation of groups over time. 
Subjects with a regurgitant volume ?55ml had a very high chance of remaining free of symptoms 
or surgery: 95% at the median time (1.6 years) and 91% at 5 years. This contrasted with 54% at 
1.6 years and 21% at 5 years for patients with regurgitant volume >55ml (p<0.0001 by logrank, 
Figure 2a). Similar differences in survival without surgery were seen for regurgitant fraction 
above and below 40%. Inclusion of an additional threshold at a regurgitant fraction of 50% 
however (dividing the cohort into 3 sub-groups of ?40%, 41-50% and >50%) revealed a further 
separation in survival without surgery, and we have illustrated this incremental risk of surgery 
with increasing regurgitant fraction in figure 2b. There were no significant differences in survival 
curves amongst the participating centres (p=0.80 by logrank test).  
LVEDV also showed a reasonable association with outcome over time, though slightly 
weaker than for measures of regurgitation (proportions surviving without surgery at the median 
of 1.6 years: 96% for LVEDVi <100ml/m2 versus 71% for ?100ml/m2; p=0.0001), Figure 2c. 
However, stratifying groups by LVEDV in addition to regurgitant volume in the survival 
analysis did not provide any further separation of the curves than those for regurgitant volume 
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alone, which was a better predictor (Figure 3a). There were only 2 subjects with high regurgitant 
volumes (>55ml) but lower LVEDVi (<100ml/m2), suggesting that in almost all cases, once a 
high volume of MR was present, LVEDV was increased (as might be expected).  
Echocardiographic grading of MR performed less well in predicting subjects who 
progressed to surgery, despite the use of quantitative assessment to guide grading where feasible 
(n=53, 49% of the total). Many of those identified as severe MR on Echo had MR volumes on 
CMR <55ml, and remained asymptomatic (n=28). There was much less of a tendency to 
underestimate the MR with Echo (compared to CMR), with only 5 subjects with moderate MR 
on Echo and regurgitant volume >55ml by CMR. Overall, if the CMR threshold of a regurgitant 
volume >55ml is used to define severe MR, 33 subjects (30% of the total) were reclassified by 
CMR compared to echocardiographic grading. The prediction of events using only quantitative 
Echo thresholds for severity (effective regurgitant orifice area above and below 0.40cm2) showed 
only modest separation of survival curves (figure 2d), though numbers in this sub-group were 
smaller (n=53), and the difference in outcome was not statistically significant. Using Echo-
derived regurgitant volume >60ml as the threshold provided very similar results (data not shown). 
Furthermore, in both moderate and severe echocardiographic MR sub-groups, there was similar 
separation of survival curves by CMR quantitation (Figure 3b). 65 subjects had follow-up 
echocardiograms during the study period and these were also analysed in the same blinded 
fashion as the initial studies. Nearly all had similar findings to the first scan, with only one 
subject who progressed to surgery showing a change in the grade of MR by Echo (from moderate 
to severe), but this may not be surprising given the tendency for the initial Echo to overestimate 
the severity of MR, highlighted above. 
Comparison with the surgical group 
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Descriptive data from all groups, including the surgical cohort, are shown in table 2. Statistical 
comparisons were not made between groups however, as the time-dependent (i.e. incomplete) 
nature of the separation into conservative and crossover groups would make this statistically 
inappropriate. The surgical cohort showed similar mean mitral regurgitation and LV volumetric 
indices to the crossover group, and both parameters were larger than in the conservative group. 
There were no significant differences in ejection fraction, or RV parameters. Systolic blood 
pressure was lower in the surgical group compared to the conservative one.  
Discussion
The association of mitral regurgitation quantitation with outcome 
Quantifying mitral regurgitation with CMR showed a strong association with the future need for 
surgery over the subsequent 5 years, demonstrating the potential value of this approach. Patients 
already destined for surgery (the ‘surgical’ group) also had measures of mitral regurgitation that 
were similar to the ‘crossover’ group, suggesting that a similar threshold of regurgitation had 
been reached in the surgical group before symptoms occurred. These CMR parameters might 
thus be useful clinical predictors of the need for surgery. In addition to the potential for high 
quantitative indices of regurgitation to identify candidates for early surgery, subjects with lower 
amounts of MR (regurgitant volume ?55ml or fraction ?40%) had a very low chance of requiring 
surgery over the subsequent few years and could be followed up less frequently, with a 
favourable impact on healthcare resources. We identified the best single thresholds to predict the 
groups with different outcomes, but it is likely that there is an increasing risk with increasing 
values of the parameters, as the separation of the three groups for mitral regurgitant fraction 
illustrate (figure 2b). The thresholds identified in this study should be treated with caution 
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however, as there are some important limitations to the study. The cohort was only a moderate 
size, and the lack of a separate validation cohort resulted in the optimal cut-off thresholds being 
derived from and applied to the same dataset. The degree of separation between groups is 
therefore likely to be optimistic and may not be as strong in other studies/cohorts. For similar 
reasons, the value of the cut-off threshold should also be treated with caution, and a validation 
cohort would be required to confirm these thresholds. 
The separation of the Kaplan-Meier event curves was slightly less pronounced than in our 
previous work in aortic regurgitation,14 and this may be due to a number of factors. Mitral 
regurgitation is dependent on other factors (e.g. fluid balance, filling pressures, LV function), 
and the quantity of MR may vary more widely over a period of time than for aortic regurgitation. 
Thus, a single measurement may show a weaker link with outcome. Secondly, the CMR 
technique for quantification is indirect and relies on both LV stroke volume measurement and 
aortic forward flow quantification, introducing more potential for error, which could also weaken 
the association with outcome. The threshold of regurgitant fraction that best differentiated the 
groups likely to progress to surgery was also higher for mitral regurgitation (40%, versus 33% 
for aortic regurgitation), which may reflect a greater ability of the left ventricle to cope with 
mitral regurgitation before the development of symptoms, particularly as the additional volume 
load is ejected into the low pressure left atrium rather than the high pressure aorta. Our findings 
also suggest that the thresholds for identifying severe mitral and aortic regurgitation should differ. 
There are currently no CMR-specific thresholds, but the AHA-ACC echocardiographic 
thresholds indicating severe regurgitant volume (60ml) and fraction (50%) are the same for both 
valve lesions.2 Interestingly, these values are close to the thresholds for the best identification of 
future symptoms in the present study, both for mitral regurgitant volume (55ml) and for fraction, 
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especially with the higher rate of progression to symptoms with a regurgitant fraction >50% 
(Figure 2b). For aortic regurgitation however, the AHA-ACC thresholds are somewhat higher 
than the optimal thresholds identified in our previous study (regurgitant fraction 33% or volume 
42ml), which may suggest that different thresholds for each valve lesion and/or CMR-specific 
thresholds should be considered.  
Comparison with LV and RV volumetric indices 
The highly accurate measurements of LVEDV by CMR showed a reasonable association with 
survival without surgery over time, but regurgitation quantification showed a better separation of 
survival curves. Further, combining LVEDV and regurgitant volume sub-groups did not improve 
survival curves over regurgitant volume alone, and subjects with low regurgitant volumes (figure 
3a) had similarly low rates of surgery irrespective of the LVEDVi. This suggests that LVEDV 
may partly be a function of the quantity of regurgitation (supported by the strong association of 
LVEDV with mitral regurgitant volume).20 This would be logical given that regurgitation is the 
physiological stimulus for LV dilation in this patient group, though is not conclusively proven 
with our data, and the several subjects with higher LVEDVi but low regurgitant volume (figure 
3a) suggests there are other factors influencing LVEDV. Despite its longstanding use in previous 
guidelines, LVESV did not have a particularly strong association with outcome. However, LV 
volumes and function are important in overall assessment and readily available from a standard 
CMR scan. LV mass showed an apparent association with progression to surgery but this 
parameter is closely related to LV volume and it was not an independent predictor. Other studies 
have not shown any predictive power of wall thickness21 and LV mass:volume ratios were 
similar for all three groups in our study, suggesting that there is no excess increase in mass over 
that required for the chamber volume increase, and that the apparent association of LV mass with 
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outcome is likely to be confounded by its close relation to LV volume. The lack of any notable 
association of RV parameters (including volumes and ejection fraction) with outcome, together 
with the similar (normal) values in all three groups, suggests that RV dilation or dysfunction may 
be a late and uncommon occurrence, and may only occur secondary to LV dysfunction and the 
resulting pulmonary hypertension. 
Systemic blood pressure 
Systemic blood pressure was lower in the crossover and surgical groups, which may reflect the 
larger mitral regurgitant volumes (and reduced aortic forward flow) in these groups. It is possible 
the lower blood pressure was a confounding factor that might have increased the chance of 
developing indications for surgery, although no previous study has suggested a causal link 
between blood pressure and the need for surgery in mitral regurgitation. Further, systolic blood 
pressure was not a good discriminator on the initial receiver operating characteristic analysis 
(area under the curve = 0.64). 
Comparison between echocardiography and CMR 
In our study, transthoracic echocardiographic grading showed a more modest ability to 
discriminate between subjects progressing to surgery and those remaining asymptomatic, with 
significant spread of the Echo grades across the conservative and crossover groups, and a 
tendency for Echo to overestimate the degree of regurgitation when compared to CMR. We were 
however only able to apply quantitative Echo grading in ~50% of subjects, and had this been 
possible in all subjects, it may have improved the results for Echo. Previous studies also suggest 
only moderate agreement between CMR and Echo,22-24 and limited reproducibility for 
quantitative Echo grading.25, 26 This may be in part due to assumptions in the PISA technique 
(the commonest Echo quantitative method). The peak PISA measurement assumes a static 
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degree of regurgitation throughout systole, and this may not hold true for some subjects, 
particularly those with mitral prolapse - this could result in over-estimation of the degree of 
regurgitation.27 Other aspects may also reduce the accuracy of PISA Echo quantitation, including 
irregular regurgitant jets (eccentrically-directed, fan-shaped/crescentic, or multiple), non-
hemispheric geometry of the PISA shell and difficulty in identifying the regurgitant orifice.26-28 
Although it is acknowledged there is no ideal gold standard for comparison, CMR quantitation of 
regurgitation has shown better intra- and inter-observer variability,29 and good agreement with 
in-vitro models23 and post-surgical LV remodelling.24 
Previous studies of outcome in mitral regurgitation 
Earlier studies examined outcomes after mitral valve surgery, demonstrating poorer 10 year 
survival following the development of symptoms3 or LV impairment,4 and poorer post-operative 
LV function once pre-operative end-systolic dimension exceeded 5.0cm (an indicator of both 
dilation and reduced function).30 These studies informed the current guideline indications for 
surgery in mitral regurgitation2 and, like the present study, highlight the value of identifying 
patients prior to symptoms or significant LV dilation/dysfunction. Chronic mitral regurgitation 
also increases left atrial size and can raise pulmonary pressure, resulting in RV dysfunction. Both 
increased atrial size21, 31 and reduced RV or biventricular function32 have been shown to predict 
medium and long term survival following mitral surgery. Reduced RV function on exercise has 
also shown some association with symptoms and outcome.33, 34 The lack of an association of RV 
function with future progression to surgery in our study might indicate that this is a late sign in 
decompensated mitral regurgitation, which is usually absent in an asymptomatic population such 
as ours – several of the previous studies involved patients with symptoms. We also did not assess 
RV function during exercise, and it is unclear whether this might explain some of the difference. 
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Few studies have predicted outcome (mostly progression to surgery) in an initially 
asymptomatic group of patients. The Mayo Clinic study11 showed a significant association of 
quantitative echocardiographic grading with prognosis (both mortality and cardiac events), 
although this study did not specifically assess the progression to cardiac surgery, which was not 
included as a cardiac event. Subjects with moderate MR also had a significant cardiac event rate 
(40%, versus 62% for severe MR), which suggests a weaker ability of quantitative Echo to 
identify patients at risk of events, and highlights the difficulty in separating moderate and severe 
mitral regurgitation in some patients - the very group examined in our study. 
Clinical utility 
Accurate assessment of the severity of mitral regurgitation and LV volumes/function is crucial in 
clinical decision making7 and CMR would already seem well suited for this. The additional 
ability to predict the onset of symptoms or other indications for surgery just prior to their 
occurrence would be clinically important, and might identify a suitable cohort for careful 
surveillance and early surgery. Conversely, patients with less severe mitral regurgitation might 
be reassured of the good medium term prognosis, and require less frequent follow-up, thereby 
improving the efficient use of healthcare resources. 
Observational studies have shown better outcomes in patients undergoing early surgery 
for mitral regurgitation,6, 35 but their limitations are well recognised. A randomised trial 
comparing early surgery with surgery based on conventional indications is required to 
demonstrate patient benefit, and our study may provide the basis for such a trial, with 
quantitative CMR indices providing the appropriate tool for identifying suitable patients.  
Limitations   
The moderate sample size and relatively small number of events limit the strength of our 
 at UNIVERSITY OF LEEDSPERIODICA on May 18, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.115.017888 
18 
conclusions, though follow up was for a reasonable period of time (mean 2.5 years, maximum 8 
years). Although the study suggests that CMR may be used to identify candidates for early mitral 
surgery, there is no evidence that operating earlier achieves a clinical benefit. This would require 
a clinical trial, which we strongly encourage. In addition, our thresholds for separating groups 
were derived from a single cohort, without a separate validation cohort to confirm the cut-points 
or the degree of separation. It is likely therefore that the degree of separation between sub-groups 
may be lower than in this study, and/or the thresholds for separating groups may vary. A 
validation cohort would be required to confirm these thresholds. In addition, the use of single 
cut-points to separate groups may underestimate the degree to which there is an incremental risk 
with increasing values of the parameters. Although we only identified further separation with 
multiple thresholds for mitral regurgitant fraction, larger sample sizes and different cohorts may 
reveal an incremental risk for other parameters. 
The lack of blinding to the CMR data in three of the investigating centres may also have 
biased outcome. However, there are no current CMR criteria/thresholds for recommending 
surgery, and we attempted to minimise bias where possible and confirmed that there were no 
significant differences in the association with the progression to surgery between centres. 
Nevertheless, remaining bias is possible, particularly given the subjective nature of symptom 
assessment. 
The echocardiographic studies were acquired for clinical purposes, and it is possible that 
these were not as comprehensive as those performed specifically for a research study might be. 
Every effort was made however to ensure the best quality assessment, including blinded re-
analysis by the researchers. 
This study relies on events over time and it is possible that some subjects assigned to the 
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‘conservative’ group were censored before they had developed symptoms. These subjects would 
be likely however to have higher degrees of mitral regurgitation, which would have likely 
resulted in a greater separation between groups if more time had occurred, rather than a reduction 
in the discriminatory ability observed in the study.  
We did not include data on subjects’ medication, and it is possible that outcome may 
have been influenced by this. However, no previous studies have shown a significant effect of 
any drug on outcome in mitral regurgitation. 
 
Conclusions
Quantification of mitral regurgitation with CMR showed a significant association with the future 
need for mitral valve surgery, and was superior to CMR-derived LV volume and 
echocardiographic grading of regurgitation. These CMR parameters might prove useful for 
identifying suitable patients for early mitral valve repair/replacement, and a randomised 
controlled trial is recommended to confirm these findings and determine clinical benefit. The 
same parameters may also be used to identify patients at low risk of future events, potentially 
facilitating reduced frequency of follow up and efficient use of healthcare resources. 
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Clinical Perspective 
Early surgery has been advocated for asymptomatic patients with severe mitral regurgitation if 
valve repair is likely, but identifying suitable patients is difficult as many would remain 
asymptomatic for years without surgery. A greater ability to identify those that might benefit 
from early surgery would be highly advantageous. We assessed the ability of cardiovascular 
magnetic resonance (CMR) quantification of mitral regurgitation to predict the development of 
symptoms or other conventional indications for surgery in the near future, as these patients might 
represent a suitable group for early surgery. 109 asymptomatic patients with echocardiographic 
moderate or severe MR had baseline CMR scans and were followed for up to 8 years. CMR 
quantification showed a strong ability to predict patients who progressed to require surgery: 91% 
of subjects with regurgitant volume ?55ml survived to 5 years without surgery compared to only 
21% with regurgitant volume >55ml (p<0.0001); and similar separation was observed for 
regurgitant fraction  below and above 40%. CMR-derived end-diastolic volumes or function did 
not add to the discriminatory power of regurgitant fraction/volume alone but are important for 
overall patient assessment. CMR may thus be able to identify patients likely to develop 
symptoms or other conventional indications for surgery in the near future, who would be an 
appropriate target group for early surgery, to avoid the potential reduced prognosis by the time 
symptoms occur. The clinical benefits of early surgery require confirmation in a clinical trial 
however. 
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Table 1. Receiver operating characteristic (ROC) data. Comparison of the ability of each CMR 
parameter to identify the initially asymptomatic patients who would develop indications for 
surgery, using receiver operating characteristic (ROC) analysis. 
AUC Threshold p Sens (%) Spec (%)
Regurgitant volume (ml) 0.81  (0.72-0.88) > 55 <0.0001 72 87 
Regurgitant volume index (ml/m2) 0.79  (0.70-0.87) > 29 <0.0001 78 82 
Regurgitant fraction (%) 0.79  (0.70-0.86) > 40 <0.0001 76 74 
LVEDV index (ml/m2) 0.75  (0.65-0.83) ? 95 <0.0001 91 56 
LV mass  (g) 0.77  (0.67-0.85) > 171 <0.0001 74 73 
LVESV index (ml/m2) 0.71  (0.61-0.79) > 36 0.0008 74 68 
LV ejection fraction (%) 0.71  (0.61-0.79) < 65 0.0006 60 76 
RV ejection fraction (%) 0.62  (0.51-0.72) <59 0.08 58 54 
AUC = area under the curve; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; LVESV = left 
ventricular end-systolic volume; RV = right ventricular; p = p value for ROC curve; Sens = sensitivity; Spec = 
specificity; threshold = value for each parameter which best identified the ‘crossover’ group using the Youden index 
for optimal sensitivity and specificity. 
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Table 2. CMR parameters by group. Comparison of CMR parameters between the three groups 
of patients with mitral regurgitation.  
Conservative Crossover Surgical 
Number in group 84 25 43 
Age  (years) 65.1  ?14.9 63.8  ?12.6 66.3  ?7.5 
Proportion of male subjects 0.65 0.76 0.60 
Proportion in atrial fibrillation 0.19 0.32 0.24 
Height  (cm) 172.8  ?10.1 174.2  ?10.4 171.3  ?9.7 
Weight  (kg) 74.8  ?12.0 75.8  ?10.6 75.2  ?14.1 
Body surface area  (m2) 1.88  ?0.18 1.89  ?0.24 1.91  ?0.17 
Heart rate (beats/min) 68.5  ?13.9 67.3  ?10.3 73.0  ?13.8 
Systolic BP (mmHg) 143.9  ?23.1 132.1  ?20.1 120.9  ?13.2  
Diastolic BP (mmHg) 77.8  ?10.8 77.4  ?8.8 73.9  ?11.3 
Regurgitant volume (ml) 39.4  ?20.0 65.9  ?23.7 70.1  ?29.5 
Regurgitant fraction (%) 32.1  ?12.4 45.7  ?11.7 46.7  ?14.0 
LVEDV  (ml) 182.7  ?50.3 224.3  ?47.8 229.1  ?49.4 
LVEDV index (ml/m2) 97.9  ?25.1 117.5  ?23.0 122.1  ?23.8 
LVESV  (ml) 62.1  ?26.1 81.8  ?29.0 82.7  ?36.7 
LVESV index (ml/m2) 33.5  ?13.8 42.5  ?13.3 44.2  ?18.3 
LV Ejection fraction (%) 66.9  ?7.6 63.9  ?7.4 64.9  ?9.3 
LV mass  (g) 144.5  ?49.9 192.9  ?46.4 192.9  ?61.6 
LV mass index (g/m2) 76.2  ?24.6 102.7  ?23.9 103.4  ?25.6 
LV mass/LVEDV ratio (g/ml) 0.83  ?0.27 0.89  ?0.17 0.87  ?0.23 
Echo LVEDD  (cm) 5.4  ?0.8 6.2  ?0.5 6.1  ?0.8 
Echo LVESD  (cm) 3.3  ?0.7 3.6  ?0.6 3.8  ?0.9 
Echo ERO (cm2) ‡ 0.58 ?0.75 0.57 ?0.28  
Echo regurgitant volume (ml) ‡ 74.3 ?73.9 89.3 ?35.8  
RVEDV (ml) 149.1  ?45.1 147.2  ?36.3 154.8  ?40.7 
RVESV (ml) 66.8  ?25.7 68.0  ?26.8 71.4  ?27.4 
RV ejection fraction (%) 56.0  ?8.5 54.1  ?9.9 52.4  ?11.3 
Values are means ±standard deviation. Note statistical comparisons are not made between groups, as the time-
dependent nature of the allocation to conservative and crossover groups would make this inappropriate. 
Abbreviations same as for table 1 except ERO = effective regurgitant orifice area. ‡ n=53 for these two parameters
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Figure Legends: 
Figure 1. CMR flow measurement in mitral regurgitation. Still frame from steady-state free 
precession cine showing left ventricular outflow tract view in systole with the mitral 
regurgitation jet (arrowed) and the slice location for aortic through-plane flow measurement 
(dashed line). LV = left ventricle, LA = left atrium, Ao = aorta. Mitral regurgitant volume is 
calculated as: LV stroke volume – aortic forward flow.  
 
Figure 2. Surgery-free survival according to mitral regurgitant volume/fraction and LVEDVi. 
Kaplan-Meier graphs for survival without surgery in 109 asymptomatic subjects with at least 
moderate mitral regurgitation initially treated conservatively and followed for up to 8 years, 
stratified by CMR-derived a) mitral regurgitant volume; b) mitral regurgitant fraction; c) LV 
end-diastolic volume index (LVEDVi); and d) echocardiographic effective regurgitant orifice 
area (Echo ERO) <0.40cm2 and ?0.40cm2 (n=53 for this group). 
 
Figure 3. a) Surgery-free survival, stratified by both CMR regurgitant volume and LVEDVi (NB 
there were too few subjects [n=2] with CMR regurgitant volume ?55ml and LVEDVi 
?100ml/m2 and this group was excluded); b) CMR regurgitant volume and echocardiographic 
MR grade. Note: the group with CMR regurgitant volume >55ml and moderate MR on echo 
contains only 5 subjects. 
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